Laurent Alric, Isabelle Ollivier‐Hourmand, Emilie Bérard, Sophie Hillaire, Maéva Guillaume, Anaı̈s Vallet-Pichard, Brigitte Bernard‐Chabert, V. Loustaud‐Ratti, Marc Bourlière, Victor de Lédinghen, I. Fouchard‐Hubert, V. Canva, Anne Minello, Eric Nguyen‐Khac, Vincent Leroy, David Saadoun, Dominique Trias, Stanislas Pol, Nassim Kamar,
... Scholar Phase 2 and 3 trials using grazoprevir (GZR), an NS3/4A protease inhibitor, and elbasvir (EBR), ... Scopus (76) Google Scholar Less than 1% of GZR+EBR is renally excreted; thus, dose adjustments of GZR+EBR are not needed for patients with nondialysis- ... advanced CKD, including subjects on hemodialysis. Once-daily GZR+EBR was highly effective, with a low rate ... account the results of the C-Surfer study, GZR+EBR is a good therapy option for this ... nominative temporary authorization (ATUn) for the use of GZR+EBR, which is an early-access program that ...
Tópico(s): Hepatitis B Virus Studies
2018 - Elsevier BV | Kidney International
Hwa-ping Feng, Luzelena Caro, Christine Fandozzi, Zifang Guo, Jennifer Talaty, Dennis Wolford, Deborah Panebianco, Marian Iwamoto, Joan R. Butterton, Wendy W. Yeh,
Abstract Elbasvir (EBR)/grazoprevir (GZR) may be coadministered with immunosuppressant drugs in posttransplant people who are infected with hepatitis C virus. The aim of the ... the safety and pharmacokinetic interactions between EBR and GZR and single doses of cyclosporine, tacrolimus, mycophenolate mofetil ( ... the presence of once‐daily EBR 50 mg/GZR 200 mg. Multiple oral doses of EBR + GZR had no significant effect on cyclosporine. However, in ... hour area under the concentration‐time curve of GZR was increased by approximately 15‐fold (geometric mean ...
Tópico(s): Renal Transplantation Outcomes and Treatments
2018 - Wiley | The Journal of Clinical Pharmacology
Ashley Brown, Christophe Hézode, Eli Zuckerman, Graham R. Foster, Amany Zekry, Stuart K. Roberts, Frederick Lahser, C. Durkan, Cyrus Badshah, B. Zhang, Michael Robertson, Janice Wahl, Emily Barr, Barbara Haber,
... SCAPE study was to evaluate elbasvir/grazoprevir (EBR/GZR), with or without ribavirin (RBV), in participants with ... participants. Participants with HCV genotype 2 infection received GZR 100 mg + RBV ± EBR 50 mg for 12 ... or 6 infection were randomized to receive EBR/GZR ± RBV for 12 weeks. The primary endpoint was ... by 80% (24/30) of those receiving EBR/GZR + RBV and 73% (19/26) of those receiving GZR + RBV. SVR rates were high in participants with HCV genotype 4 infection receiving EBR/GZR with and without RBV (100% [10/10] and ...
Tópico(s): Hepatitis B Virus Studies
2017 - Wiley | Journal of Viral Hepatitis
... boceprevir, telaprevir, simeprevir (SMV), paritaprevir, ASV, and grazoprevir (GZR); 4 HCV NS5A inhibitors including ledipasvir (LDV), ombitasvir, ... an RO2 negative drug (Table 1). EBR and GZR combination regimen is available as a fixed dose ... phase clinical development program when higher doses of GZR were evaluated in combination with PEG-IFN/RBV. This led to the regulatory decision that the GZR dose should not exceed 100 mg/d in ... 208261Orig1s000CrossR.pdf. Accessed July 1, 2016.Google Scholar GZR exposures (area under the curve at 24 hours) ...
Tópico(s): Liver Disease Diagnosis and Treatment
2017 - Elsevier BV | Gastroenterology
Abu ul Hassan S. Rana, Hyun‐Seok Kim,
Previous studies on Ga-doped ZnO nanorods (GZRs) have failed to address the change in GZR morphology with increased doping concentration. The morphology-change affects the GZR surface-to-volume ratio and the real essence ... provide an optimum morphological trade-off to n-GZR/p-Si heterostructure characteristics. The GZRs were grown via one of the most eminent ... of an optimum amount of NH₄OH to synchronize GZR aspect and surface-to-volume ratio. Hence, the ... changed morphology, on the optoelectronic characteristics of n-GZR/p-Si heterostructures. The doped nanostructures were characterized ...
Tópico(s): Quantum Dots Synthesis And Properties
2017 - Multidisciplinary Digital Publishing Institute | Materials
Jan Šperl, Gábor Horváth, Waldemar Halota, Juan Arenas Ruiz-Tapiador, Adrian Streinu‐Cercel, Ligita Jančorienė, Klára Werling, Hege Kileng, Seyfettin Köklü, Jan Gerstoft, Petr Urbánek, Robert Flisiak, Rafael Alexander Leiva, Edita Kazėnaitė, R Prinzing, Sushma Patel, Jingjun Qiu, Ernest Asante‐Appiah, Janice Wahl, Bach‐Yen Nguyen, Eliav Barr, Heather Platt,
... the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) with sofosbuvir plus pegylated interferon/ribavirin (SOF/PR) ... were randomized to receive 12 weeks of EBR/GZR 50 mg/100 mg once daily (n = 129) ... and 90.5% (114/126) in the EBR/GZR and SOF/PR groups, respectively. The estimated adjusted ... zero, both non-inferiority and superiority of EBR/GZR vs. SOF/PR were established. The frequency of ... safety events was lower among patients receiving EBR/GZR than SOF/PR (0.8% vs. 27.8%, ... were randomized to receive 12 weeks of EBR/GZR 50 mg/100 mg once daily (n = 129) ...
Tópico(s): Liver Disease Diagnosis and Treatment
2016 - Elsevier BV | Journal of Hepatology
AbdullahS Alghamdi, Mohammed Alghamdi, FaisalM Sanai, Hamdan S. Alghamdi, Faisal Abaalkhail, Khalid Alswat, Mohammed A. Babatin, Adel Alqutub, Ibrahim Altraif, Faleh Alfaleh,
... asunaprevir, and a second-generation PI is grazoprevir (GZR) NS5A inhibitors that bind to domain 1 of ... SMV, PTV/OBV and/or DSV or EBR/GZR as HCV therapy Patients with severe renal impairment ( ... by 32%. Conversely, tenofovir increases PTV by 24%. GZR is an HCV NS3/4A PI and a ... OATP1B1/3 transporters. The related drug interactions of GZR/EBR combination have been mentioned in the EBR ... other UGT1A1 substrates.[39] EBR is combined with GZR, an HCV NS3/4A PI, and both are ... P-gp in the absorption of EBR and GZR appears to be minimal. EBR/GZR are contraindicated ...
Tópico(s): Hepatitis B Virus Studies
2016 - Medknow | Saudi Journal of Gastroenterology
Elamin H. Elbasha, Michael Robertson, C. Nwankwo,
... GT1a)-infected patients treated with elbasvir/grazoprevir (EBR/GZR) for 12 weeks, but not patients treated with EBR/GZR and ribavirin (RBV) for 16 weeks.To assess ... of baseline testing for NS5A RAVs in EBR/GZR-treated patients compared without testing, and with current ... We simulated the course of treatment with EBR/GZR, ledipasvir/sofosbuvir (LDV/SOF) and ombitasvir/paritaprevir/ritonavir+ ... sensitivity analyses.RAVs testing-guided treatment with EBR/GZR resulted in more QALYs than EBR/GZR without testing, 3D+RBV, or LDV/SOF8. This ...
Tópico(s): Chronic Lymphocytic Leukemia Research
2016 - Wiley | Alimentary Pharmacology & Therapeutics
Luzelena Caro, Larissa Wenning, Zifang Guo, Iain P. Fraser, Christine Fandozzi, Jennifer Talaty, Deborah Panebianco, Maureen Ho, Naoto Uemura, Christina Reitmann, Peter Angus, Edward Gane, Thomas Marbury, William B. Smith, Marian Iwamoto, Joan R. Butterton, Wendy W. Yeh,
Grazoprevir (GZR) plus elbasvir is an approved treatment for chronic infection with hepatitis C virus (HCV) genotype 1 or ... evaluate the pharmacokinetics and safety of multiple-dose GZR (200, 100, or 50 mg) in non-HCV ... panel pharmacokinetic study. Participants received oral doses of GZR 200 mg (two 100-mg tablets), 100 mg ( ... each hepatic cohort. Participants with HI demonstrated higher GZR exposure than healthy matched controls and showed an ... exposure with increasing HI severity. The steady-state GZR AUC0-24 (area under the concentration-time curve ...
Tópico(s): Drug-Induced Hepatotoxicity and Protection
2017 - American Society for Microbiology | Antimicrobial Agents and Chemotherapy
Shelby Corman, Elamin H. Elbasha, Steven N. Michalopoulos, Chizoba Nwankwo,
... cost-utility of treatment with elbasvir/grazoprevir (EBR/GZR) regimens compared with ledipasvir/sofosbuvir (LDV/SOF), ombitasvir/ ... constructed to evaluate the cost-utility of EBR/GZR ± RBV over a lifetime time horizon from the ... outcome was incremental cost-utility ratio for EBR/GZR ± RBV versus available oral direct-acting antiviral agents. ... to test the robustness of the model.ResultsEBR/GZR ± RBV was economically dominant versus LDV/SOF in all patient populations. EBR/GZR ± RBV was also less costly than SOF/VEL ...
Tópico(s): Liver Disease Diagnosis and Treatment
2017 - Elsevier BV | Value in Health
Hiromitsu Kumada, Yoshiyuki Suzuki, Yoshiyasu Karino, Kazuaki Chayama, Norifumi Kawada, Takeshi Okanoue, Yoshito Itoh, Satoshi Mochida, Hidenori Toyoda, Hitoshi Yoshiji, Shintaro Takaki, Naoyoshi Yatsuzuka, Etsuo Yodoya, Takashi Iwasa, Go Fujimoto, Michael Robertson, Stuart Black, Luzelena Caro, Janice Wahl,
Elbasvir (EBR) in combination with grazoprevir (GZR) has demonstrated efficacy in patients with hepatitis C virus (HCV) infections in trials primarily conducted in the USA and Europe. We investigated ... safety and efficacy of EBR in combination with GZR in Japanese patients with chronic HCV infection, with ... to receive EBR (50 mg) in combination with GZR (50 or 100 mg) once daily for 12 ... or deferred treatment with EBR (50 mg) and GZR (100 mg, determined in part 1) for 12 ... were randomized to receive EBR in combination with GZR at a dose of 50 mg (n = 31) ...
Tópico(s): Systemic Lupus Erythematosus Research
2016 - Springer Science+Business Media | Journal of Gastroenterology
Ira M. Jacobson, Fred Poordad, Roberto Firpi-Morell, Gregory T. Everson, Elizabeth C. Verna, S. Bhanja, Peggy Hwang, Luzelena Caro, Michael Robertson, Edgar D. Charles, Heather Platt,
... C-SALT study assessed elbasvir (EBR) plus grazoprevir (GZR) in individuals with HCV genotype 1 infection and ... CP-B cirrhosis received EBR 50 mg plus GZR 50 mg once daily, and a control group of noncirrhotic participants received EBR 50 mg plus GZR 100 mg once daily. The primary endpoint was ... in drug exposure between groups, despite the differing GZR dose. Adverse events occurring in >10% of participants ... clinical interest occurred. CONCLUSIONS: EBR 50 mg plus GZR 50 mg once daily for 12 weeks was ... population. TRANSLATIONAL IMPACT: Although EBR plus reduced-dose GZR is not available for people with CP-B ...
Tópico(s): HIV/AIDS drug development and treatment
2019 - Lippincott Williams & Wilkins | Clinical and Translational Gastroenterology
Edward Gane, Ronald Nahass, Velimir A. Luketic, Ernest Asante‐Appiah, Peggy Hwang, Michael Robertson, Janice Wahl, Emily Barr, Barbara Haber,
Elbasvir (EBR; HCV NS5A inhibitor) and grazoprevir (GZR; HCV NS3/4A protease inhibitor) are approved as a fixed-dose combination to treat patients chronically infected with HCV genotypes 1 and 4. ... by in vitro potency, the efficacy of EBR+GZR was assessed in HCV GT3-infected patients. This ... tolerability of 12 or 18 weeks of EBR+GZR with ribavirin (RBV) in treatment-naïve, noncirrhotic HCV ... received open-label EBR (50 mg once daily) + GZR (100 mg once daily) + RBV. The primary efficacy ... 34.0, 78.2) after treatment with EBR+GZR+RBV for 12 weeks or 18 weeks, respectively. ...
Tópico(s): Hepatitis B Virus Studies
2017 - Wiley | Journal of Viral Hepatitis
Elamin H. Elbasha, Wayne Greaves, David Roth, C. Nwankwo,
... once-daily oral regimen of elbasvir/grazoprevir (EBR/GZR) for 12 weeks was found to be a ... CKD. We evaluated the cost-effectiveness of EBR/GZR in treatment-naïve and treatment-experienced CKD patients ... from published studies. Cost of treatment with EBR/GZR and peg-INF/RBV were based on wholesale ... utility ratios (ICUR). The model predicted that EBR/GZR will significantly reduce the incidence of liver-related ... NoTx or use of peg-IFN/RBV. EBR/GZR-based regimens resulted in higher average remaining QALYs ... not cost-effective, and the ICUR of EBR/GZR compared with NoTx was $13 200/QALY. Treatment ...
Tópico(s): HIV/AIDS drug development and treatment
2016 - Wiley | Journal of Viral Hepatitis
Chen‐Hua Liu, Cheng‐Yuan Peng, Yu‐Jen Fang, Wei‐Yu Kao, Sheng‐Shun Yang, Cheng‐Kuan Lin, Hsueh‐Chou Lai, Wen‐Pang Su, Sheng‐Uei Fang, Chun‐Chao Chang, Tung‐Hung Su, Chun‐Jen Liu, Pei‐Jer Chen, Ding‐Shinn Chen, Jia‐Horng Kao,
... the efficacy and tolerability of elbasvir/grazoprevir (EBR/GZR) for East-Asian hepatitis C virus genotype 1b ( ... 40 HCV GT1b hemodialysis patients who received EBR/GZR for 12 weeks at 6 academic centers in ... affecting SVR12 were analyzed. The tolerability for EBR/GZR was also assessed. The SVR12 rates by ITT ... of these events were judged related to EBR/GZR. The common AEs included upper respiratory tract infection ( ... 5, in whom one (2.5%) had EBR/GZR-induced late ALT elevation. No patients developed hyperbilirubinemia ...
Tópico(s): Liver Disease Diagnosis and Treatment
2020 - Nature Portfolio | Scientific Reports
Toshie Mashiba, Kouji Joko, Masayuki Kurosaki, Hironori Ochi, Chitomi Hasebe, Takehiro Akahane, Tetsuro Sohda, Keiji Tsuji, Akeri Mitsuda, Hiroyuki Kimura, Ryoichi Narita, Chikara Ogawa, Koichiro Furuta, Masaya Shigeno, Hiroaki Okushin, Hiroshi Ito, Atsunori Kusakabe, Takashi Satou, Chiharu Kawanami, Ryo Nakata, Haruhiko Kobashi, Takashi Tamada, Yasushi Ide, Hitoshi Yagisawa, Atsuhiro Morita, Tomomichi Matsushita, Kazuhiko Okada, Namiki Izumi,
... combined with the NS3/4A protease inhibitor grazoprevir (GZR) in patients with hepatitis C virus (HCV) genotype ... post‐treatment (SVR12) and the safety of EBR/GZR treatment in 159 men and 194 women with ... were responsible for selecting candidate patients for EBR/GZR in this retrospective study. Results Treatment outcomes for EBR/GZR were good in direct‐acting antiviral (DAA)‐naïve ... No serious adverse events were observed with EBR/GZR therapy. Conclusions The SVR rate of EBR/GZR would have been 100% in patients without either ...
Tópico(s): HIV/AIDS drug development and treatment
2019 - Wiley | Hepatology Research
Debra T. Choi, Amy Puenpatom, Xian Yu, Kevin F. Erickson, Fasiha Kanwal, Hashem B. El–Serag, Jennifer R. Kramer,
Randomized controlled trials of EBR/GZR have reported high treatment efficacy, safety and tolerability in patients undergoing dialysis. However, real world effectiveness data for EBR/GZR in this population is lacking. We evaluated the effectiveness of EBR/GZR in an HCV-infected population with all stages ... with chronic HCV genotype 1 infection with EBR/GZR prescriptions dispensed during February 1, 2016-August 31, ... who met eligibility criteria and completed a EBR/GZR treatment course (≥11 weeks). Approximately 73.2% (n = ...
Tópico(s): Hepatitis B Virus Studies
2019 - Elsevier BV | Antiviral Research
Graham R. Foster, Kosh Agarwal, Matthew Cramp, Sulleman Moreea, Stephen T. Barclay, Jane Collier, Ashley Brown, Stephen Ryder, Andrew Ustianowski, Daniel Forton, Ray Fox, Fiona Gordon, William Rosenberg, David Mutimer, Jiejun Du, Christopher L. Gilbert, Ernest Asante‐Appiah, Janice Wahl, Michael Robertson, Eliav Barr, Barbara Haber,
... the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) plus sofosbuvir (SOF) with and without ribavirin (RBV) ... open-label study. Treatment-naive participants received EBR/GZR + SOF + RBV for 8 weeks or EBR/GZR + SOF for 12 weeks, and peginterferon/RBV treatment-experienced participants received EBR/GZR + SOF ± RBV for 12 weeks or EBR/GZR + SOF for 16 weeks. The primary endpoint was ... from this study support the use of EBR/GZR plus SOF for 12 weeks without RBV for ...
Tópico(s): Hepatitis B Virus Studies
2018 - Lippincott Williams & Wilkins | Hepatology
Satoshi Miuma, Hisamitsu Miyaaki, Akihiko Soyama, Masaaki Hidaka, Mitsuhisa Takatsuki, Hidetaka Shibata, Naota Taura, Susumu Eguchi, Kazuhiko Nakao,
Aim Recently, elbasvir/grazoprevir combination therapy (EBR/GZR) was reported to have excellent antiviral effects for chronic genotype 1 hepatitis C virus (HCV) infection. However, it has not been recommended for ... interactions. Methods We report the usage of EBR/GZR in five post‐LT HCV re‐infected patients ... n = 19). Results All patients treated with EBR/GZR therapy obtained rapid virologic response and sustained at ... induction. To evaluate the antiviral effects of EBR/GZR therapy for these patients, we compared them to ...
Tópico(s): HIV/AIDS drug development and treatment
2018 - Wiley | Hepatology Research
Dorota Zarębska‐Michaluk, Jerzy Jaroszewicz, Iwona Buczyńska, Krzysztof Simon, Beata Lorenc, Magdalena Tudrujek‐Zdunek, Krzysztof Tomasiewicz, Marek Sitko, Aleksander Garlicki, Ewa Janczewska, Dorota Dybowska, Waldemar Halota, Małgorzata Pawłowska, Paweł Pabjan, Włodzimierz Mazur, Agnieszka Czauż‐Andrzejuk, Hanna Berak, Andrzej Horban, Łukasz Socha, Jakub Klapaczyński, Anna Piekarska, Maria Blaszkowska, Teresa Belica‐Wdowik, Beata Dobracka, Olga Tronina, Zbigniew Deroń, Jolanta Białkowska, Łukasz Laurans, Robert Flisiak,
Grazoprevir/elbasvir (GZR/EBR) was approved for the treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infected patients ... The aim of this study was to assess GZR/EBR regimen in the real-world experience, particularly ... treatment-experienced.The analysis included patients treated with GZR/EBR selected from 10 152 individuals from the ... online.A total of 1615 patients who started GZR/EBR therapy in 2017 and 2018 with a ... mild and did not lead to therapy discontinuation.GZR/EBR treatment carried-out in patients infected with ...
Tópico(s): Hepatitis B Virus Studies
2019 - Wiley | Journal of Gastroenterology and Hepatology
Tzu‐Cheng Tsai, Shin‐Tarng Deng, Chao‐Wei Hsu,
Abstract Background Elbasvir/grazoprevir (EBR/GZR) is a new generation, fixed‐dose, combination antiviral drug used in chronic hepatitis C virus (HCV) genotype (GT) 1 or 4 ... evaluates the clinical efficacy and safety of EBR/GZR after its launch in Taiwan. Methods This is ... retrospective observational study. Patients who had received EBR/GZR for chronic HCV GT 1 between June 2017 ... had HCV GT 1a; most of the EBR/GZR‐related side effects in this study were mild. ... RNA level. Conclusions This study confirmed that EBR/GZR is safe and effective for treating patients with ...
Tópico(s): Liver Disease Diagnosis and Treatment
2019 - Wiley | Journal of Medical Virology
Yasue Takeuchi, Norio Akuta, Hitomi Sezaki, Fumitaka Suzuki, Shunichiro Fujiyama, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada,
... direct‐acting antiviral agents (DAAs) elbasvir/grazoprevir (EBR/GZR) is associated with high sustained virologic response (SVR). ... evaluate the safety and treatment efficacy of EBR/GZR in hepatitis C virus (HCV)‐infected patients. Methods ... who were treated with EBR (50 mg) plus GZR (100 mg) once daily for 12 weeks. The ... not detected after failure of retreatment with EBR/GZR. Conclusion Treatment with EBR/GZR was highly efficacious with acceptable safety, even in ...
Tópico(s): HIV/AIDS drug development and treatment
2018 - Wiley | Hepatology Research
Jacob George, Eduard Burnevich, I‐Shyan Sheen, Jeong Heo, Nguyễn Văn Kính, Tawesak Tanwandee, Pin‐Nan Cheng, Do Young Kim, Won Young Tak, Svetlana Kizhlo, К. В. Жданов, Isakov Va, Liwen Liang, Pauline A. Lindore, Joy Ginanni, Bach‐Yen Nguyen, Janice Wahl, Eliav Barr, Michael Robertson, Paul Ingravallo, Rohit Talwani,
... the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) in participants with HCV infection from Asia‐Pacific ... 6 infection were randomized to EBR 50 mg/GZR 100 mg (immediate‐treatment group [ITG]) or placebo ( ... adverse events was similar between participants receiving EBR/GZR and placebo (50.8% versus 51.2%; difference, − ... confidence interval, −12.3, 11.9). Conclusion: EBR/GZR for 12 weeks provides an effective and well‐ ... for the large population with GT1b infection. EBR/GZR is not recommended for the treatment of individuals ...
Tópico(s): Liver Disease Diagnosis and Treatment
2018 - Lippincott Williams & Wilkins | Hepatology Communications
Xinyi Ng, Chizoba Nwankwo, Jean Marie Arduino, Shelby Corman, Kathryn Lasch, Jacqueline Mary Lustrino, Sushma Patel, Heather Platt, Jingjun Qiu, Jan Šperl,
... to compare the impact of elbasvir/grazoprevir (EBR/GZR) treatment versus sofosbuvir with pegylated interferon and ribavirin ( ... were randomized 1:1 to receive either EBR/GZR or SOF/PR for 12 weeks. Patients self- ... Compared to the SOF/PR group, the EBR/GZR group reported more improvement in scores across all ... baseline scores or above posttreatment. Treatment with EBR/GZR did not impact fatigue scores, but treatment with ... This study demonstrated that HCV treatment with EBR/GZR resulted in a significantly better PRO profile as ...
Tópico(s): Chronic Lymphocytic Leukemia Research
2018 - Dove Medical Press | Patient Preference and Adherence
Lawrence Serfaty, Ira M. Jacobson, Jürgen K. Rockstroh, Frederick L. Altice, Peggy Hwang, Eliav Barr, Michael Robertson, Barbara Haber,
... 800 000 IU / mL receive elbasvir/grazoprevir ( EBR / GZR ) for 12 weeks, and those with baseline viral load >800 000 IU / mL receive EBR / GZR plus ribavirin for 16 weeks. This analysis was ... sensitive or specific stratification factor for defining EBR / GZR regimens. In this post hoc, integrated analysis, participants ... GT 1a infection who received EBR 50 mg/ GZR 100 mg for 12 weeks were stratified according ... more individuals to receive the 12‐week EBR / GZR regimen without compromising the opportunity for SVR.
Tópico(s): Chronic Lymphocytic Leukemia Research
2018 - Wiley | Journal of Viral Hepatitis
Christophe Hézode, Massimo Colombo, Marc Bourlière, Ulrich Spengler, Ziv Ben‐Ari, Simone I. Strasser, William M. Lee, Leslie Morgan, Jingjun Qiu, Peggy Hwang, Michael Robertson, Bach‐Yen Nguyen, Eliav Barr, Janice Wahl, Barbara Haber, Robert A. Chase, Rohit Talwani, V. Di Marco,
... the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) in patients with inherited bleeding disorders and HCV ... oral, once‐daily, fixed‐dose combination of EBR/GZR 50 mg/100 mg for 12 weeks and ... ratio values were similar in patients receiving EBR/GZR and placebo; among patients with hemoglobinopathies, change in ... hemoglobin levels was similar in those receiving EBR/GZR compared to those receiving placebo. Conclusion : These results ... the expanding pool of data available for EBR/GZR, indicating a high level of efficacy and favorable ...
Tópico(s): Blood groups and transfusion
2017 - Lippincott Williams & Wilkins | Hepatology
Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang,
... the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) administered for 12 weeks in Korean patients who ... enrolled at Korean study sites in four EBR/GZR phase 3 clinical trials. Patients were treatment-naive ... A cirrhosis. All patients received EBR 50 mg/GZR 100 mg once daily for 12 weeks. The ... an AEs. Conclusions In this retrospective analysis, EBR/GZR administered for 12 weeks was well-tolerated and ...
Tópico(s): Liver Disease Diagnosis and Treatment
2019 - Korean Association for the Study of the Liver | Clinical and Molecular Hepatology
Christine M. Durand, Mary G. Bowring, Diane Brown, Michael A. Chattergoon, Guido Massaccesi, Nichole Bair, Russell Wesson, Ashraf Reyad, Fizza Naqvi, Darin Ostrander, Jeremy Sugarman, Dorry L. Segev, Mark Sulkowski, Niraj M. Desai,
... results. All recipients received a dose of grazoprevir (GZR), 100 mg, and elbasvir (EBR), 50 mg, immediately ... from donors with genotype 1 infection continued receiving GZR–EBR for 12 weeks after transplantation; those receiving ... 3 infection had sofosbuvir, 400 mg, added to GZR–EBR for 12 weeks of triple therapy. Measurements: ... was the incidence of adverse events related to GZR–EBR treatment. The primary efficacy outcome was the ...
Tópico(s): Hepatitis B Virus Studies
2018 - American College of Physicians | Annals of Internal Medicine
Marta Hernández‐Conde, Inmaculada Fernández, Christie Perelló, Adolfo Gallego, Martín Bonacci, J.M. Pascasio, Manuel Romero‐Gómez, Susana Llerena, Conrado Fernández‐Rodríguez, José Luis Castro Urda, Luisa García Buey, Isabel Carmona, Rosa M. Morillas, Nuria Domínguez García, Francisco Gea, J.A. Carrión, José Castellote, J.M. Moreno Planas, Belén Piqueras Alcol, Esther Molina, M. Diago, Silvia Montoliu, Juan de la Vega, Fernando Menéndez, Juan José Sánchez‐Ruano, Javier García‐Samaniego, José Miguel Rosales Zábal, María Dolores Antón, Ester Badía, Raquel Souto‐Rodríguez, Francisco Salmerón, Miguel Fernández‐Bermejo, Blanca Figueruela, José Javier Moreno‐Palomares, José Luís Calleja,
... patients with chronic HCV infection, elbasvir/grazoprevir ( EBR / GZR ) demonstrated high cure rates and a good safety ... study assessed the effectiveness and safety of EBR / GZR , with and without ribavirin, in a real‐world ... 2016 and May 2017, and treated with EBR / GZR with at least end‐of‐treatment response data, ... in a real‐world setting in Spain, EBR / GZR achieved high rates of SVR 12, comparable to ...
Tópico(s): Chronic Lymphocytic Leukemia Research
2018 - Wiley | Journal of Viral Hepatitis
Franck Maunoury, Aurore Clément, Chizoba Nwankwo, L. Lévy-Bachelot, Armand Abergel, Vincent Di Martino, Éric Thervet, Isabelle Durand‐Zaleski,
... the cost-effectiveness of the elbasvir/grazoprevir (EBR/GZR) regimen in patients with genotype 1 chronic hepatitis ... and grazoprevir compared to no-treatment. Results EBR/GZR increased the number of life years (6.3 ... chronic hepatitis C and chronic kidney disease. EBR/GZR without interferon and ribavirin, produced the greatest benefit ... Based on shape of the acceptability curve, EBR/GZR can be considered cost-effective at a willingness ...
Tópico(s): Chronic Lymphocytic Leukemia Research
2018 - Public Library of Science | PLoS ONE